We recently traveled to Nashville, Tennessee for a State of the Science Summit™ on Genitourinary Malignancies. At the meeting, faculty from Vanderbilt-Ingram Cancer Center shared insight on recent developments in prostate cancer. Specifically, panelists discussed selection criteria for androgen receptor-directed agents in nonmetastatic castration-resistant prostate cancer and explained how a population-based study has the potential to inform decision making in localized prostate cancer.

Moreover, faculty assessed some of the long-anticipated treatment advances made in metastatic urothelial cancer and discussed the breadth of therapeutic options available in renal cell carcinoma, as well as the patient factors that are used to inform treatment selection.